| Identification | Back Directory | [Name]
Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with 3-[[(3S)-3-(aminomethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-1-propanol (1:1) | [CAS]
1234563-15-5 | [Synonyms]
Epetraborole R-Mandelate
Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with 3-[[(3S)-3-(aminomethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaborol-7-yl]oxy]-1-propanol (1:1) | [Molecular Formula]
C19H24BNO7 | [MOL File]
1234563-15-5.mol | [Molecular Weight]
389.21 |
| Hazard Information | Back Directory | [Uses]
Epetraborole R-mandelate is a novel leucyl-tRNA synthetase (LeuRS) inhibitor (IC50=0.31 μM), thereby inhibiting protein synthesis. Epetraborole R-mandelate can be used in multidrug-resistant gram-negative pathogens infection research[1][2][3]. | [References]
[1] Goldstein EJ, et al. Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms. Antimicrob Agents Chemother. 2013 May;57(5):2401-4. DOI:10.1128/AAC.02580-12
[2] O'Dwyer K, et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. DOI:10.1128/AAC.03774-14
[3] Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52. DOI:10.1111/j.1749-6632.2011.06323.x |
|
|